Screener
Design Therapeutics, Inc. DSGN Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development (including related party amounts of $72 and $228, respectively) | $14,379 | $15,377 |
| General and administrative (including related party amounts of $85 and $134, respectively) | 5,327 | 5,041 |
| Total operating expenses | 19,706 | 20,418 |
| Loss from operations | (19,706) | (20,418) |
| Interest income | 2,070 | 2,703 |
| Net loss | $(17,636) | $(17,715) |
| Net loss per share, basic and diluted | $(0.29) | $(0.31) |
Item 1. Financial Statements.
FAQ
- What is Design Therapeutics, Inc.'s other operating expenses?
- Design Therapeutics, Inc. (DSGN) reported other operating expenses of $19.71M in Q1 2026.
- How has Design Therapeutics, Inc.'s other operating expenses changed year-over-year?
- Design Therapeutics, Inc.'s other operating expenses decreased by 3.5% year-over-year, from $20.42M to $19.71M.
- What is the long-term trend for Design Therapeutics, Inc.'s other operating expenses?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s other operating expenses has grown at a 22.0% compound annual growth rate (CAGR), from $35.83M to $79.47M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Design Therapeutics, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude